ClinicalTrials.gg
CompletedNCT07312643PASIPHY_PENUpdated Feb 4, 2026

Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

A Phase 1 interventional study of Pasireotide cartridge with reusable ServoPen and Pasireotide ampule with syringe in Pharmacokinetics and Safety, sponsored by RECORDATI GROUP. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by RECORDATI GROUP · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This single-center Phase 1 study in healthy male and female subjects of 18 to 55 years (inclusive) will follow an open-label, randomized, single-dose, crossover design with 2 intervention periods. The purpose of this study is to assess and compare the pharmacokinetic characteristics and the safety of single doses of pasireotide when administered subcutaneously by reusable ServoPen with cartridge or by syringe drawn from an ampule in healthy subjects.

Read the detailed description

Study details include:

  • The study duration will be approximately 6.5 weeks per subject.
  • Two (2) intervention periods are planned per dose level (50 µg and 200 µg), with 1 of the following interventions administered per period:

    • Single dose of 50 µg pasireotide administered subcutaneously using reusable ServoPen with cartridge.
    • Single dose of 200 µg pasireotide administered subcutaneously using reusable ServoPen with cartridge.
    • Single dose of 50 µg pasireotide administered subcutaneously using syringe drawn from an ampule.
    • Single dose of 200 µg pasireotide administered subcutaneously using syringe drawn from an ampule.
  • The screening examination will be performed within 28 to 2 days prior to the first administration of study intervention.
  • Subjects will stay in-house for at least 3 days per period.
  • The ambulatory follow-up visit will be performed within 7 to 10 days after the last administration of study intervention.
02

Conditions studied

  • Pharmacokinetics
  • Safety

Keywords

  • pasireotide
  • subcutaneous
  • bioavailability
03

In context

Lead sponsor

RECORDATI GROUP is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • A subject is eligible only if all of the following criteria apply:

    1. Age of 18 to 55 years inclusive, at the time of signing the .
    2. ≥18.5 kg/m2.
    3. Male or female. use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

      a. Male subjects: Male subjects are eligible to participate if they agree to the following starting from the first administration of study intervention until the follow-up visit:

      • Refrain from donating semen. Plus, either:

      o Abstain from sexual intercourse with a partner of (definition in Section 10.5.1 of Study Protocol (SP)). OR

      o During sexual intercourse with a partner of childbearing potential, use a male condom and counsel the partner to use a highly effective contraceptive method (definitions in Section 10.5.2 of SP).

      b. Female subjects: A female subject is eligible to participate if she is neither pregnant nor breastfeeding, and one of the following conditions applies:

      • or has been sterilized more than 3 months ago (definitions in Section 10.5.1 of SP). OR
      • Uses a highly effective (with a failure rate of \<1% per year) contraceptive method, preferably with low user dependency, as described in Section 10.5.2 during study participation and for at least 30 days after the last administration of study intervention and agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.

      ❑General Health Status

    4. Overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs and .
    5. Clinically acceptable clinical laboratory test results.

      ❑Smoking

    6. Non-smoker, which includes abstinence from using other nicotine-containing products (e.g., nicotine patches, chewing gum, e-cigarettes) for at least the last 3 months prior to first administration of study intervention.

      • Informed Consent
    7. Capable of giving signed informed consent as described in Section 10.1 of SP, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol prior to any clinical study-specific procedure.

      EXLCUSION:

      Subjects are excluded from the study if any of the following criteria apply:

      • Medical Conditions

    <!-- -->

    1. Any history or evidence of any and/or other major disease or as determined by medical evaluation (including physical examination) capable of significantly altering the absorption, metabolism, or elimination of drugs, constituting a risk when taking the study intervention or interfering with the interpretation of data.
    2. for the use of pasireotide in medical history, such as ≥ moderate hepatic impairment ( B), hypocortisolism, uncontrolled diabetes, heart failure ≥ Class III, cardiogenic shock, second- or third-degree AV block, sinoatrial block, sick sinus syndrome, severe bradycardia or congenital long syndrome.
    3. Medical history of pituitary disorder.
    4. History or presence of cholelithiasis and/or acute or chronic pancreatitis.
    5. Any clinically relevant history of allergic conditions requiring hospitalization or prolonged systemic treatment (including drug allergies, drug , asthma, eczema, allergies requiring therapy with or anaphylactic reactions), excluding allergic contact sensitizations (e.g., nickel allergy). Subjects with uncomplicated seasonal allergic rhinitis can be accepted if the expected allergy season is clearly outside the study period.
    6. Known or suspected hypersensitivity to study interventions or any component of the formulations used.
    7. Clinically relevant chronic or acute infectious illness or febrile illness within the last 14 days prior to first administration of study intervention.
    8. Evidence of COVID-19 signs or symptoms or confirmed COVID-19 infection within the last 14 days prior to first administration of study intervention.
    9. Tendency for vasovagal reactions (e.g., after venipuncture) or history of syncope.

      • Diagnostic Assessments
    10. Positive for surface antigen, antibody or anti- 1 + 2 antibodies and HIV 1 p24 antigen.
    11. Positive test for alcohol or drugs of abuse.
    12. Positive pregnancy test in female subjects.
    13. Supine systolic blood pressure >140 mmHg or 90 mmHg or 90 bpm or tympanic body temperature 37.6°C.
    14. 12-lead ECG with clinically relevant abnormality or showing a QTcF>450 ms for male or >470 ms for female subjects, PR >215 ms or QRS >120 ms.
    15. Fasting glucose ≥ 5.5 mmol/L at screening and/or > at screening.
    16. ≥1.5 x ULN, AST ≥1.5 x ULN or serum ≥1.5 x ULN.
    17. calculated based on the Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation
    18. Thyroid disorders as evidenced by TSH outside normal range and confirmed by free triiodothyronine and free thyroxine outside normal range. Subjects with suspected compensated thyroid hormone formation disorders as indicated by TSH outside normal range but free triiodothyronine and free thyroxine within normal range may be included at the discretion of the Investigator.
    19. Hypokalemia (potassium ≤ 3.5 mmol/L).
    20. Hypomagnesemia (magnesium \< 0.7 mmol/L).

      ❑Prior/Concomitant Therapy

    21. Use of any concomitant medication or any drugs / medicines (including dietary supplements, natural and herbal remedies) within the last 14 days or 5 times their elimination half-life prior to first administration of study intervention, whichever is longer. Allowed treatments are the use of contraceptives as outlined in Section 10.5 of SP and HRT if the subject has been on stable treatment for at least 3 months and continues treatment throughout the study. Additionally, the occasional use of paracetamol (up to 2 g per day) and ibuprofen (up to 1.6 g per day) are allowed.

      ❑Prior/Concurrent Clinical Study Experience

    22. Use of any drug or participation in any clinical study within 30 days or 5 times the half-life of the study drug administered in a previous study, whichever is longer, prior to the expected date of first administration of study intervention.
    23. Previous randomization in this study.

      ❑Other Exclusions

    24. Higher than low-risk alcohol consumption i.e., consumption of an average weekly alcohol intake of >14 units/week for men (daily dose of >24 g, weekly dose of >168 g) and >7 units/week for women (daily dose of >12 g, weekly dose of >84 g). One unit (12 g) corresponds to 0.3 L of beer/day or 0.12 L of wine/day or 2 cL of spirits/day.
    25. History of drug or alcohol abuse within the last 6 months.
    26. Excessive consumption of caffeine- or xanthine-containing food or beverages (>5 cups of coffee a day or equivalent) or inability to stop consuming within 48 h prior to planned administration of study intervention
    27. Intake of food, beverages, or other products containing grapefruit, grapefruit juice, grapefruit hybrids, star fruit, Seville orange, tangelo, pomelo, or exotic citrus fruits within 14 days prior to planned administration of study intervention.
    28. Consumption of poppy seed containing food within the last 72 h prior to the first administration of study intervention.
    29. Vegetarian, vegan, or restricted diet (e.g., gluten-free) or not willing or able to eat the standard meals provided.
    30. Donation or blood collection of more than 450 mL of blood or blood products or acute loss of blood within the last 30 days prior to the first administration of study intervention.
    31. Strenuous physical activity within the last 72 h prior to the first administration of study intervention.
    32. Employee of the Sponsor, the Nuvisan Group, or other CRO involved in the clinical study.
    33. Legal incapacity or limited legal capacity, or incarceration.
    34. Inability to understand or communicate reliably with the Investigator or considered by the Investigator to be unable to or unlikely to co-operate with the protocol requirements, instructions, and study-related restrictions.
    35. Any other conditions or factors which in the opinion of the Investigator may interfere with study conduct.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ServoPen 50 µg

    Single dose of 50 µg pasireotide administered subcutaneously using reusable ServoPen with cartridge.

    Combination Product: Pasireotide cartridge with reusable ServoPen

  • Experimental
    ServoPen 200 µg

    Single dose of 200 µg pasireotide administered subcutaneously using reusable ServoPen with cartridge.

    Combination Product: Pasireotide cartridge with reusable ServoPen

  • Active comparator
    Syringe 50 µg

    Single dose of 50 µg pasireotide administered subcutaneously using syringe drawn from an ampule.

    Drug: Pasireotide ampule with syringe

  • Active comparator
    Syringe 200 µg

    Single dose of 200 µg pasireotide administered subcutaneously using syringe drawn from an ampule.

    Drug: Pasireotide ampule with syringe

Interventions

  • Combination productPasireotide cartridge with reusable ServoPen

    Pasireotide cartridge with reusable ServoPen

  • DrugPasireotide ampule with syringe

    Pasireotide ampule with syringe

06

What researchers measure

Primary outcomes

  1. AUC0-tlast

    To investigate the relative bioavailability (Frel) of pasireotide s.c. after single-dose administration of 2 dose levels using reusable ServoPen with cartridge (Test 1 and Test 2) compared to single-dose administration of 2 dose levels using syringe drawn from an ampule (Reference 1 and Reference 2).

    Time frame: 2 weeks

  2. AUC0-inf

    To investigate the relative bioavailability (Frel) of pasireotide s.c. after single-dose administration of 2 dose levels using reusable ServoPen with cartridge (Test 1 and Test 2) compared to single-dose administration of 2 dose levels using syringe drawn from an ampule (Reference 1 and Reference 2).

    Time frame: 2 weeks

  3. Cmax

    To investigate the relative bioavailability (Frel) of pasireotide s.c. after single-dose administration of 2 dose levels using reusable ServoPen with cartridge (Test 1 and Test 2) compared to single-dose administration of 2 dose levels using syringe drawn from an ampule (Reference 1 and Reference 2).

    Time frame: 2 weeks

07

Study locations

1 site
  • Nuvisan GmBH
    Neu-Ulm, 89231, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Feb 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 31, 2025
StartActual
Dec 1, 2025
Primary completionActual
Feb 3, 2026
CompletionActual
Feb 3, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07312643
Lead sponsor
RECORDATI GROUP
Collaborators
Nuvisan
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Dec 1, 2025
Primary completion
Feb 3, 2026
Completion
Feb 3, 2026
Last update
Feb 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion